Life Sciences

life sciences industry

Today’s life sciences industry faces myriad challenges, including complex regulation, steep competition and ever-changing technologies. Companies around the world turn to Ropes & Gray’s global life sciences group for internationally recognized counsel on virtually all matters impacting their businesses.


“A distinguishing characteristic of Ropes & Gray is the degree to which the firm’s corporate capabilities combine with deep experience in regulatory matters and government investigations. Their team is broad and deep and they have shown a terrific willingness to deliver cost-effective service in unique ways.” LMG Life Sciences
“Sources say the firm brings a breadth of experience and business judgment to transactions.” Chambers Global
“A fact repeatedly pointed out- the firm maintains a stellar reputation for expertise across regulatory and transactional law.” LMG Life Sciences


The attorneys and technical specialists who make up the global life sciences group understand the unique needs of a wide range of clients in the dynamic life sciences industry. We work across practices and geographies to develop cutting-edge solutions that help our clients meet their business goals.

In addition to advising biotechnology, pharmaceutical and medical device companies, we also work with:

Drawing on resources in our offices around the globe, we focus on developing cutting-edge solutions to help clients meet their business goals. Our practice includes:


Ropes & Gray’s life sciences team has handled every type of transaction from licensing agreements with a small biotechnology company to large mergers of industry-leading pharmaceutical and medical device companies around the globe. Recent noteworthy transactions include representation of:

  • Pfizer on its $14 billion acquisition of Medivation Inc., a biopharmaceutical company focused on developing and commercializing small molecules for oncology.
  • Shire in its agreement with Baxalta Incorporated to combine the companies for an aggregate consideration of approximately $32 billion. Baxalta, headquartered in Northern Illinois, is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology, and immunology.
  • Boehringer Ingelheim in a $595 million global license and collaboration agreement with AbbVie to jointly develop and commercialize a biologic IL-23 antibody for the treatment of psoriasis and other immunological indications.
  • Vertex Pharmaceuticals in its $2.6 billion strategic research and collaboration agreement with CRISPR Therapeutics.
  • Pacira Pharmaceuticals in First Amendment and APA challenges to FDA’s assertions that the company engaged in “off-label” promotion of its flagship product, a post-surgical analgesic.  As a result, FDA agreed to withdraw its warning letter and revise the label to clarify that the challenged claims were permissible.
  • The Broad Institute of MIT and Harvard in a global licensing agreement with Monsanto Company for the use of the CRISPR-Cas genome-editing technology in agriculture. The agreement is the Broad Institute’s first commercial license for use of the CRISPR technology in agriculture.
  • Pfizer on its definitive agreement to acquire Hospira, an Illinois-based leading provider of injectable drugs and infusion technologies, for approximately $17 billion in the all-cash deal.
  • Novavax Inc., a clinical-stage vaccine company, which focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants, in its $300 million convertible notes offering.
  • Sarepta Therapeutics in its $584 million exclusive license and collaboration agreement with Summit Therapeutics for the European rights to Summit’s utrophin modulator pipeline for the treatment of Duchenne Muscular Dystrophy.
  • Cubist Pharmaceuticals in connection with its $9.5 billion sale to Merck.
  • Wright Medical Technology in its $3.3 billion merger with Tornier NV, creating a new company to be called Wright Medical Group NV, based in the Netherlands. Proteostasis Therapeutics in a $1.2 billion worldwide collaboration deal to develop and commercialize Infinity’s duvelisib for the treatment of patients with cancer.